bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in San Antonio, TX, US. The stock last traded at $0.47, down 2.49% on the session, giving a market capitalisation of $3.0M. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of -257.3%. Its beta of -1.05 implies it has historically moved less than the broad market.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
bioAffinity Technologies, Inc. is most often compared with the following Healthcare names: